• MCL-1’s Canonical Role in Breast Cancer

  2026-09-01

  Campbell and colleagues show that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK-mediated mitochondrial cell death. Genetic deletion and pharmacological inhibition both impaired tumor growth, while removal of BAX and BAK prevented these effects, providing a mechanistic rationale for apoptosis-focused MCL-1 inhibitor research.

• ABT-263 (Navitoclax): From Priming to Proof

  2026-09-01

  A translational framework for using ABT-263 (Navitoclax) to connect Bcl-2 family dependence, mitochondrial priming, caspase activation, and emerging evidence that Pol II degradation can trigger cell death independently of transcriptional loss.

• Sabutoclax for Reliable Apoptosis Assays

  2026-08-31

  Learn how Sabutoclax, SKU A4199, can improve interpretation of viability, proliferation, and cytotoxicity assays by linking concentration–response data with orthogonal apoptosis measurements. This scenario-based guide covers assay design, formulation, controls, data interpretation, and practical supplier selection.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-08-31

  This case report describes radiologic reduction of metastatic lymph nodes in intra-abdominal desmoplastic small round cell tumor after anlotinib treatment, providing the first published clinical signal for this otherwise poorly standardized disease. Its main value is hypothesis generation: it connects a multi-target tyrosine kinase inhibitor with a rare, aggressive sarcoma while clearly requiring validation in larger and controlled studies.

• Firefly Luciferase mRNA: A Systems Assay Guide

  2026-08-30

  Firefly Luciferase mRNA (ARCA, 5-moUTP) is more than a luminescent reporter: its chemistry, handling, delivery vehicle, and substrate exposure jointly determine assay quality. This guide connects transcript design with freeze–thaw formulation science to improve experimental interpretation and reproducibility.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-08-29

  HyperPFU™ high-fidelity DNA polymerase is a proofreading DNA polymerase for accurate amplification of long, GC-rich, inhibitor-affected, or otherwise difficult templates. It is appropriate for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or polymerase-generated sticky ends.

• HyperScript™ Reverse Transcriptase in qPCR

  2026-08-28

  This scenario-driven guide explains how SKU K1071, HyperScript™ Reverse Transcriptase, supports RNA-to-cDNA conversion when viability, proliferation, or cytotoxicity studies produce ambiguous biological readouts. It connects engineered reverse-transcription features with structured RNA, low-input samples, protocol control, and responsible qPCR interpretation.

• Pazopanib Hydrochloride Assay Workflows

  2026-08-28

  Build more informative oncology assays with Pazopanib Hydrochloride by separating growth inhibition from true cell killing. This workflow combines multi-target kinase biology, anti-angiogenic model design, compound-handling guidance, and orthogonal readouts for renal cell carcinoma and soft tissue sarcoma research.

• GSDMC and Pyroptosis-Based Risk Modeling in PAAD

  2026-08-27

  Yan et al. integrated pyroptosis-related gene expression, survival modeling, immune estimation, and drug-sensitivity prediction to define a prognostic framework for pancreatic adenocarcinoma. The study highlights GSDMC as a candidate therapeutic target and identifies PD.173074 among compounds warranting experimental follow-up, while emphasizing that the drug result is computational rather than clinical evidence.

• BODIPY 581/591 C11 for Cardiac Oxidative Stress

  2026-08-27

  Translate membrane lipid oxidation into a quantitative red-to-green fluorescence ratio with BODIPY 581/591 C11. This workflow is tailored to acute myocardial infarction models, helping researchers distinguish lipid peroxidation from broader reactive oxygen species signals and evaluate nanozyme or antioxidant interventions.

• Wnt/NR2F2 Drives Platinum Resistance in Brain Metastasis

  2026-08-26

  The reference study identifies a Wnt/NR2F2/GPX4 axis that enables lung cancer-derived brain metastatic cells to consume glutathione rapidly, suppress ferroptosis, and acquire platinum resistance. Its integrated metabolomics, proteomics, functional rescue, and transcriptional assays connect brain metastatic adaptation with a therapeutically relevant redox mechanism.

• Breast Cancer Dependence on MCL-1: Study Insights

  2026-08-26

  This study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic control of BAX/BAK-mediated mitochondrial cell death. Genetic deletion and pharmacological inhibition both restricted tumor growth, while additional data connected MCL-1 with breast cancer stem cell activity and tumor stemness markers.

• ABT-263 and the Hidden Biology of Caspase-3

  2026-08-25

  ABT-263 (Navitoclax) is best known as a potent Bcl-2 family inhibitor that exposes mitochondrial apoptotic dependencies. Its greater translational value may emerge when researchers connect that mechanism to the non-apoptotic biology of caspase-3, including cancer cell motility. This article presents a framework for using ABT-263 in apoptosis assays, cancer biology studies, resistance profiling, and migration-focused experiments without confusing apoptotic loss of viability with direct anti-motility activity.

• RIPostC, Ketone Bodies, and Ferroptosis in Stroke

  2026-08-25

  The 2024 ACS Chemical Neuroscience study identifies ketone body production as a mechanistic link between remote ischemic postconditioning and protection from ischemic stroke. Its rat and neuronal-cell experiments connect improved energy metabolism with reduced ferroptosis, offering a framework for testing defined ketone-body interventions in neuroprotection research.

• Sabutoclax Workflows for Apoptosis Profiling

  2026-08-24

  Sabutoclax is a membrane-permeable pan-Bcl-2 inhibitor suited to experiments that separate growth arrest from genuine cell killing. This practical guide pairs dose–response testing with time-resolved apoptosis measurements, mechanistic controls, and troubleshooting for cancer-cell and translational studies.

8025 records 1/535 page Next 12345 下5页 Last page